52
Participants
Start Date
January 31, 2011
Primary Completion Date
December 31, 2014
Study Completion Date
December 31, 2014
RAD001
"RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis. RAD001 tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of RAD001 orally with a glass of water at regular intervals at the same time in the morning after a light, nonfat breakfast."
Placebo
"Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10. Matching placebo tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of the matching placebo orally with a glass of water at regular intervals at the same time in the morning after a light, nonfat breakfast."
Cincinnati Children's Hospital Medical Center, Cincinnati
Boston Children's Hospital, Boston
Collaborators (1)
Tuberous Sclerosis Alliance
OTHER
Autism Speaks
OTHER
Novartis Pharmaceuticals
INDUSTRY
Seizure Tracker LLC
UNKNOWN
Mustafa Sahin
OTHER